PLX Protalix BioTherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: PLX

Price (delayed)

$2.03

Market cap

$116.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.31

Enterprise value

$132.79M

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to ...

Highlights
PLX's EPS has surged by 50% year-on-year and by 16% since the previous quarter
PLX's net income is up by 46% year-on-year and by 16% since the previous quarter
Protalix BioTherapeutics's equity has shrunk by 76% YoY but it has increased by 8% QoQ
Protalix BioTherapeutics's quick ratio has decreased by 35% YoY and by 3.5% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.protalix.com
Peers: FOLD NBIX PFE TEVA

Key stats

What are the main financial stats of PLX
Market
Shares outstanding
57.35M
Market cap
$116.43M
Enterprise value
$132.79M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.79
Earnings
Revenue
$47.64M
EBIT
-$13.01M
EBITDA
-$11.93M
Free cash flow
-$25.63M
Per share
EPS
-$0.31
Free cash flow per share
-$0.53
Book value per share
-$0.21
Revenue per share
$0.98
TBVPS
$1.15
Balance sheet
Total assets
$55.79M
Total liabilities
$66.43M
Debt
$33.47M
Equity
-$10.64M
Working capital
$12.45M
Liquidity
Debt to equity
-3.15
Current ratio
1.38
Quick ratio
0.83
Net debt/EBITDA
-1.37
Margins
EBITDA margin
-25%
Gross margin
58.9%
Net margin
-31.3%
Operating margin
-27.3%
Efficiency
Return on assets
-24.7%
Return on equity
N/A
Return on invested capital
-28.2%
Return on capital employed
-55.7%
Return on sales
-27.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PLX stock price

How has the Protalix BioTherapeutics stock price performed over time
Intraday
-1.46%
1 week
9.73%
1 month
30.13%
1 year
118.26%
YTD
48.18%
QTD
48.18%

Financial performance

How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$47.64M
Gross profit
$28.05M
Operating income
-$13.01M
Net income
-$14.93M
Gross margin
58.9%
Net margin
-31.3%
PLX's net margin has soared by 56% YoY and by 17% from the previous quarter
The operating margin has increased by 49% YoY and by 20% from the previous quarter
PLX's net income is up by 46% year-on-year and by 16% since the previous quarter
Protalix BioTherapeutics's operating income has increased by 36% YoY and by 20% QoQ

Growth

What is Protalix BioTherapeutics's growth rate over time

Valuation

What is Protalix BioTherapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
2.07
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.79
PLX's EPS has surged by 50% year-on-year and by 16% since the previous quarter
Protalix BioTherapeutics's equity has shrunk by 76% YoY but it has increased by 8% QoQ
PLX's price to sales (P/S) is 73% higher than its last 4 quarters average of 1.2 and 22% higher than its 5-year quarterly average of 1.7
Protalix BioTherapeutics's revenue has increased by 24% YoY

Efficiency

How efficient is Protalix BioTherapeutics business performance
PLX's return on sales is up by 49% year-on-year and by 16% since the previous quarter
The return on invested capital has increased by 29% year-on-year and by 18% since the previous quarter
The ROA has grown by 18% YoY and by 10% from the previous quarter

Dividends

What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PLX.

Financial health

How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 16% smaller than its total liabilities
Protalix BioTherapeutics's quick ratio has decreased by 35% YoY and by 3.5% QoQ
The company's current ratio fell by 26% YoY but it rose by 3.8% QoQ
Protalix BioTherapeutics's equity has shrunk by 76% YoY but it has increased by 8% QoQ
The debt to equity is up by 43% year-on-year but it has declined by 9% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.